saturday - april 12
| 09.00 - 12.00 | SCIENTIFIC SESSION V | |
| Chairs: J.D. ADACHI & F. GUILLEMIN | ||
| 09.00 - 09.30 | Plenary lecture | |
| Bone forming agents: one objective, many roads | ||
| W. DERE | ||
| 09.30 - 10.00 | Oral Communications selected from abstracts | |
09:30–09:40 OC44 |
OSTABOLIN-C™ INCREASES LUMBAR SPINE AND HIP BMD AFTER 1 p YEAR OF THERAPY: RESULTS OF A PHASE II CLINICAL TRIAL A. Hodsman, H. Bone, C. Gallagher, D. Kendler, J. Brown, S. Greenspan, C.L. p Barclay, P. Morley, R. Anderson, B. MacDonald |
|
09:40–09:50 OC45 |
DIFFERENCES IN EFFICACY AND SAFETY OF GENERIC AND ORIGINAL BRANDED ONCE WEEKLY BISPHOSPHONATES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS |
|
09:50–10:00 OC46 |
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ODANACATIB (MK-822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH LOW BMD: 18-MONTH RESULTS |
|
| 10.00 - 10.30 | Plenary lecture | |
| Mechanisms of skeletal fragility in males | ||
| P. SZULC | ||
| 10.30 - 11.00 | Oral Communications selected from abstracts | |
10:30–10:40 OC47 |
CLINICAL IMPLICATIONS OF GLUCOSAMINE SULFATE AND GLUCOSAMINE HYDROCHLORIDE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES |
|
10:40–10:50 OC48 |
ABDOMINAL AORTIC CALCIFICATION (AAC) ON VERTEBRAL FRACTURE ASSESSMENT (VFA) IMAGES PREDICTS INCIDENT MYOCARDIAL INFARCTION (MI) AND STROKE INDEPENDENT OF CLINICAL CARDIOVASCULAR DISEASE RISK FACTORS |
|
10:50–11:00 OC49 |
STRONTIUM RANELATE DEMONSTRATES EFFICACY AGAINST HIP FRACTURE OVER 3 AND 5 YEARS IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF HIP FRACTURE |
|
| 10.30 - 12.00 | NICE Guidelines : Clinical and economic implications | |
NICE and the implication for UK and elsewhere. |
||
NICE or nasty? |
||
| Debate | ||
| 12.15 - 13.45 | Discovery of new uses for DXA | |
| Lunch Symposium sponsored by HOLOGIC | ||
| Chair: P.D. DELMAS | ||
| IVA is an independent predictor of both future cardiovascular disease events and fractures |
||
| E. McCLOSKEY | ||
| Vertebral fracture - Clinical evidence of compromised bone quality | ||
| P.D. DELMAS | ||
| Two and three dimensional bone structure measurements with DXA | ||
| M. BOUXSEIN | ||
| 13.45 - 15.00 | Poster Session & Exhibition Viewing Posters P350 to P475 will be manned |
|
| 14.00 - 15.00 | Meet-The-Professor Session | |
| Who will benefit from calcium/vitamin D supplementation - B. DAWSON -HUGUES How to monitor anti-osteoporosis treatment ? - R. RIZZOLI Management of glucocorticoid-induced osteoporosis - S. PAPAPOULOS Role of the orthopaedic surgeon in the management of osteoporosis - T. EINHORN |
||
| 15.00 - 16.30 | ESCEO - GREES The role of the orthopaedic surgeons in the management of osteoporosis: Bone Fracture Healing Symposium organised by the Group for the Respect of Ethics and Excellence in Science (GREES) Introduction Part I: Critical issues in translational and clinical research for the study of new technologies to enhance bone repair
Part II: Guidelines on the evaluation of medicinal products aiming at improving bone fracture healing in osteoporotic patients
Panel discussion
|
|
| 15.00 - 18.00 | Meeting of the Turkish National Scientific Societies | |
| 15.00 - 16.30 | The Role of Physiatrists in the Management of Osteoporosis : Building a bridge between primary and tertiary prevention of osteoporosis
|
|
| Chairs: A. GÜRLEK, S. AKIN | ||
| The importance of peak bone mass - S. TÜZÜN | ||
| Genetics of osteoporosis - D.G. YAVUZ | ||
| Falls and Fractures - Ü. AKARIRMAK | ||
| Rehabilitation strategies in osteoporosis - G. AKYÜZ | ||
| 16.45 - 18.00 | Multi-disciplinary approach to osteoporosis Management | Meeting of the Turkish Society of Obstetrics and Gynecology |
| Chairs: F. ATALAY, F. KORKUSUZ | Relationship of menopause and osteoporosis – A gynecologist point of view | |
| Endocrinologist’s point of view - T. SÖZEN | Chair: A. BALOGLU | |
| Orthopedic’s point of view - S. ATIK | Speakers: B. TIRAS, H. GÜNER, I. METE ITIL, C. DEMIR | |
| Physiatrist’s point of view - A. ORAL | Epidemiology of Osteoporosis in Turkey and in the Developing World H. GÜNER |
|
Approaches to the Prevention of Bone Fragility in Postmenopausal Women I. ITIL |
||
Hormon Replacement Therapy and Osteoporosis B. TIRA? |
||